Navigation Links
Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
Date:6/15/2012

NEW YORK, June 15, 2012 /PRNewswire/ -- ExL Pharma will host the 2nd Pharmaceutical Research Collaborations Summit August 14-15 at the Hyatt Harborside in Boston.

One of the critical questions facing the pharmaceutical industry today is where will future R&D dollars come from. The patent cliff and other forces are making it difficult for large pharmaceutical companies to maintain large-scale internal research departments.  As a result, pharmaceutical companies frequently look outside of their company to benefit from discoveries that may be further along the development pipeline, reducing the financial risk of bringing them further.

The two-day program focuses on various strategies pharmaceutical companies take to benefit from outside research. Sessions will highlight case studies on partnerships between large pharmaceutical and biotech companies, universities, small biotechs, and virtual pharma companies.  Panelists will discuss the different goals of the different institutions, venture capital opportunities, and intellectual property considerations.  Attendees will hear presentations on open innovation case studies, regulatory issues, and the finer points of alliance management.

The diverse speaker staff draws from some of the leading life science research institutions and companies, including MIT, Abbott Ventures, Boston University, Biogen Idec, Tufts, Merck, Millennium, Novartis, Yale, Pfizer, Sanofi, and more. These different points of view will shed light on the dynamics that promise to drive scientific research in coming years.

To find out more information regarding attending the 2nd Pharmaceutical Research Collaborations Summit, please contact Shari Gelfand on sgelfand@exlpharma.com or visit 2nd Pharmaceutical Research Collaborations Summit.

About ExL Pharma

ExL Pharma, a division of ExL Events, Inc., is the industry leader in developing innovative, educational conferences that serve the pharmaceutical and allied healthcare communities in the United States, Europe, Latin America and various markets. Behind our diverse pharmaceutical event portfolio, ExL's experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality events designed to exceed the dynamic informational and networking needs of specific audiences and working groups.

Press Contact:
Shari Gelfand
(917) 258-5145
sgelfand@exlpharma.com


'/>"/>
SOURCE ExL Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
2. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
3. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Genesis Biopharma Mentioned Favorably in BioMedReports Article
5. Genesis Biopharma Issues Letter To Shareholders
6. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
7. Questcor Pharmaceuticals Expands Repurchase Program
8. PharmAthene Reports First Quarter 2012 Financial Results
9. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
10. PDL BioPharma to Present at Upcoming Conferences
11. China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):